The American Journal of Managed Care

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

Adagrasib received accelerated FDA approval in December 2022 as a targeted therapy for patients with locally advanced or metastatic NSCLC with a KRAS G12C mutation who have had at least 1 prior ...
Seeking Alpha

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

PITTSBURGH, April 22, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS) (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the first patient was dosed ...
Seeking Alpha

Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer

SAN DIEGO, Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) ® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data ...
Business Insider

Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency

PITTSBURGH, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development, and ...